Finck Brian N
Center for Human Nutrition and Center for Cardiovascular Research, Washington University School of Medicine, 660 South Euclid Avenue, Campus Box 8031, St. Louis, MO 63110, USA.
Cardiovasc Res. 2007 Jan 15;73(2):269-77. doi: 10.1016/j.cardiores.2006.08.023. Epub 2006 Sep 1.
Myocardial energy metabolism is an important determinant of cardiac structure and function. Modulating metabolism is therefore an attractive therapeutic avenue for the treatment of cardiac disease. The peroxisome proliferator-activated receptor family (PPARalpha, beta/delta, gamma) of nuclear receptor transcription factors is an important regulator of cardiac metabolism and has been targeted for pharmacologic therapies designed to modulate metabolism. The PPARs control myocardial metabolism by transcriptionally regulating genes encoding enzymes involved in fatty acid and glucose utilization. The expression and activity of the PPARs and their coactivator protein PGC-1alpha is dynamically regulated in several cardiomyopathic and metabolic diseases. This review will summarize these findings and other recent studies regarding the effects of experimental PPAR activation and deactivation and its potential impact on cardiomyopathic remodeling.
心肌能量代谢是心脏结构和功能的重要决定因素。因此，调节代谢是治疗心脏病的一个有吸引力的治疗途径。核受体转录因子的过氧化物酶体增殖物激活受体家族（PPARα、β/δ、γ）是心脏代谢的重要调节因子，已成为旨在调节代谢的药物治疗靶点。PPARs通过转录调控参与脂肪酸和葡萄糖利用的酶的编码基因来控制心肌代谢。在几种心肌病和代谢性疾病中，PPARs及其辅激活蛋白PGC-1α的表达和活性受到动态调节。本综述将总结这些发现以及其他关于实验性PPAR激活和失活的影响及其对心肌病重塑潜在影响的近期研究。
